
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
It is indicated for patients with susceptible isocitrate dehydrogenase-1 (IDH1) mutations confirmed by a test method approved by the FDA.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:153
Exkivity is suitable for specific non-small cell lung cancer(NSCLC).【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:131
Broad-spectrum antitumor agents【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:83
Ixazomab is suitable for the treatment of multiple myeloma.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:168
It is mainly used for the treatment of chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and certain types of acute myeloid leukaemia (AML).【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:99
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:139
司帕生坦、Sparsentan、LuciSeta、Filspari、斯帕森坦【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:199
Suitable for treating severe alopecia areata in adults and adolescents aged 12 and above.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:107
Used for the treatment of advanced, unresectable cholangiocarcinoma with FGFR2 gene fusion or rearrangement.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:110
Treat RET gene fusion positive NSCLC and MTC.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:181
Treat non-small cell lung cancer, medullary thyroid carcinoma, and thyroid cancer caused by RET gene mutations.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:128
Enasidenib is suitable for Leukemia.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:162
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Dr···【more】
Recommended:[list:visits]2026-24-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended:[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended:[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended:[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended:[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended:[list:visits]2026-16-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643